Search results for "From ACP Journal Club"
Dapagliflozin reduced cardiorenal outcomes but not MACE in T2 diabetes with or at risk for atherosclerotic CVD
Baseline kidney disease, albuminuria, and cardiovascular disease (CVD) status may help determine which patients will benefit most from sodium-glucose cotransporter-2 inhibitors, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/11/08/7.htm
8 Nov 2019
Studies show benefits of glucagon-like peptide-1 receptor agonists
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
https://diabetes.acponline.org/archives/2019/10/11/7.htm
11 Oct 2019
In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years
These long-term follow-up data show no legacy effect from intensive glucose control on cardiovascular (CV) events, differing from the results of the United Kingdom Prospective Diabetes Study, an ACP Journal Club commentary noted.
https://diabetes.acponline.org/archives/2019/10/11/8.htm
11 Oct 2019
In type 2 diabetes, a primary care–led weight management program increased weight loss and diabetes remission at 2 years
Primary care practices that want to adopt such an intervention for their patients will need a dietician or practice nurse to deliver an intensive weight loss program, noted an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/8.htm
13 Sep 2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
The trial showed that an oral glucagon-like peptide-1–receptor analogue improved glycemic control compared to a dipeptidyl peptidase 4 inhibitor, but gastrointestinal side effects and cost remain barriers to use of the former class.
https://diabetes.acponline.org/archives/2019/09/13/7.htm
13 Sep 2019
Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/09/13/6.htm
13 Sep 2019
Review: Viscous fiber reduces HbA1c, fasting glucose, and insulin resistance in type 2 diabetes
An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
https://diabetes.acponline.org/archives/2019/06/14/6.htm
14 Jun 2019
In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year
Putting these findings into practice may require incorporating dental professionals into diabetes care teams and training clinicians who treat patients with diabetes to recognize and assess periodontal disease and make appropriate referrals, the ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2019/05/10/8.htm
10 May 2019
Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes
The review shows that, contrary to specialty recommendations, there is no reason not to use regular human insulins, which are less costly than analogue insulins, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/05/10/7.htm
10 May 2019
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function
The results of the CANVAS trial are promising for patients with type 2 diabetes mellitus (T2DM) and early chronic kidney disease, but ongoing research should provide more convincing data, said an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2019/03/08/6.htm
8 Mar 2019